22nd Century Group Inc (XXII)

2.24
0.20 9.80
AMEX : Health Care
Prev Close 2.04
Open 2.06
Day Low/High 2.00 / 2.29
52 Wk Low/High 0.56 / 1.75
Volume 4.80M
Avg Volume 2.60M
Exchange AMEX
Shares Outstanding 102.76M
Market Cap 208.60M
EPS -0.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

22nd Century Group Files 2017 Second Quarter Report And Announces Conference Call To Provide Business Update

22nd Century Group Files 2017 Second Quarter Report And Announces Conference Call To Provide Business Update

22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is focused on tobacco harm reduction and cannabis research, announced today the Company's second quarter 2017 financial results and will...

FDA's Plan To Lower Nicotine In Cigarettes Has Captured The Attention Of Regulators And Public Health Experts Around The World

FDA's Plan To Lower Nicotine In Cigarettes Has Captured The Attention Of Regulators And Public Health Experts Around The World

22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is focused on tobacco harm reduction, announced today that, as reported in Bloomberg News, the landmark plan by the United States Food and...

Don't Buy Altria's Dip Following FDA Regulation Change, RBC Says

Don't Buy Altria's Dip Following FDA Regulation Change, RBC Says

This FDA regulatory change hasn't created a buying opportunity like past changes have.

FDA's Plan To Lower Nicotine In Cigarettes To Non-Addictive Levels Shines Spotlight On 22nd Century Group

FDA's Plan To Lower Nicotine In Cigarettes To Non-Addictive Levels Shines Spotlight On 22nd Century Group

22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is focused on tobacco harm reduction, stated today that the Company welcomes the announcement by the United States Food and Drug...

Tobacco Stocks Go Up in Smoke After FDA Issues Plan to Curb Tobacco-Related Deaths

Tobacco Stocks Go Up in Smoke After FDA Issues Plan to Curb Tobacco-Related Deaths

The FDA wants to protect children and limit tobacco-related diseases by changing the way cigarettes are made.

22nd Century Joins Russell Microcap® Index

22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced that, effective today, the Company joined the Russell Microcap ® Index, when FTSE Russell...

22nd Century Receives Guidance From FDA On Phase III Clinical Trials

22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced today that on June 20, 2017, the Company and its wholly owned subsidiary, Heracles...

22nd Century Partners With The University Of Virginia To Utilize Industrial Hemp To Clean Up And Reclaim Polluted Lands

22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company focused on tobacco harm reduction and cannabis research, announced today that, together with The University of Virginia (UVA), it has launched a...

22nd Century Meets With FDA On Modified Risk Tobacco Product Application For World's Lowest Nicotine Tobacco Cigarettes

22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced today that the Company and its wholly-owned subsidiary, Goodrich Tobacco Company, held yesterday...

New International Survey Shows Overwhelming Support For Very Low Nicotine Cigarettes

22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is focused on tobacco harm reduction and cannabis research, announced today that the Company commissioned Harris Poll to conduct an international...

22nd Century And Dent Neurosciences Research Center To Partner On Brain Imaging Clinical Trial

22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is focused on tobacco harm reduction and cannabis research, announced today that it has signed a collaborative research agreement with The Dent...

22nd Century Produces Non-GMO Very Low Nicotine Tobacco

22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is focused on tobacco harm reduction and cannabis research, announced today that the Company's research collaboration with North Carolina State...

22nd Century Group Receives Order For 2.4 Million SPECTRUM® U.S. Government Research Cigarettes

22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is focused on tobacco harm reduction and cannabis research, announced today that its wholly-owned subsidiary, Goodrich Tobacco Company, received...

There Has Been A Dramatic Surge In The Number Of Publications Relating To 22nd Century's Proprietary Very Low Nicotine (VLN) Cigarettes. (Graphic: Business Wire)

22nd Century Group, Inc. (NYSE MKT: XXII) announced today that there has been a dramatic surge in the number of publications relating to the Company's proprietary Very Low Nicotine (VLN) cigarettes.

22nd Century Raises 2017 Revenue Projection To $16Million - Another Record Year

22nd Century Group, Inc. (NYSE MKT: XXII ), a plant biotechnology company, announced today that the Company's wholly-owned subsidiary, NASCO Products, recently entered into substantial new manufacturing agreements for the...

22nd Century Group Files 2017 First Quarter Report And Announces Conference Call To Provide Business Update

22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is focused on tobacco harm reduction and cannabis research, announced today the Company's first quarter 2017 financial results and will provide a...

FDA Authorizes Clinical Trial For 22nd Century's BRAND B Low Tar-to-Nicotine Ratio Cigarettes

22nd Century Group, Inc. (NYSE MKT : XXII), announced today that the U.

22nd Century Accepted To Present Proprietary Smoking Cessation Product At BIOCHINA Partnering Forum In Zhuhai, China

22nd Century Group, Inc. (NYSE MKT : XXII), a plant biotechnology company that is focused on tobacco harm reduction and cannabis research, announced today that James Vail, the Company's Director of Business Development,...

22nd Century Will Play Leading Role In Industrial Hemp Industry

22nd Century Group, Inc. (NYSE MKT : XXII), a plant biotechnology company that is focused on tobacco harm reduction and cannabis research, announced today that the Company is building on its newly developed THC-free...

World-Renowned Smoking Cessation Scientist, Dr. Michael Cummings, To Present Keynote Address At 22nd Century Annual Shareholder Meeting

22nd Century Group, Inc. (NYSE MKT : XXII), a plant biotechnology company that is focused on tobacco harm reduction and cannabis research, announced today that K.

New Zealand Study Recommends 22nd Century's VLN Cigarettes As An Effective Tobacco Control Strategy

22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is focused on tobacco harm reduction and cannabis research, announced today that the journal Nicotine and Tobacco Research has published a new...

Collect Smokin' Hot Profits From This Marijuana Biotech

Collect Smokin' Hot Profits From This Marijuana Biotech

This innovative biotech offers investors an intriguing play on the medical marijuana business.

22nd Century's "Non- Or Minimally-Addictive" Cigarettes Gaining Support Of Leading Tobacco Scientists Around The World

22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is focused on tobacco harm reduction and cannabis research, announced today that leading scientists published more than 12 new studies involving...

22nd Century Invited To Speak At The Colorado Hemp Expo About The Company's Medical Marijuana Initiatives And Zero-THC Hemp Plants

22nd Century Group, Inc. (NYSE MKT: XXII), a leader in tobacco harm reduction and cannabis research, announced today that representatives of the Company's wholly-owned subsidiary, Botanical Genetics, have been invited to...

22nd Century Produces Zero THC Industrial Hemp At Anandia Labs

22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is focused on tobacco harm reduction and cannabis research, announced today that the Company's research collaboration with strategic partner...

22nd Century Group Issues Annual Letter To Shareholders

22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is focused on tobacco harm reduction and cannabis research, announced today that the Company has issued the following letter to shareholders as...

22nd Century Group Files 2016 Annual Report And Announces Conference Call To Provide Business Update

22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is focused on tobacco harm reduction and cannabis research, announced today that the Company filed its 2016 Annual Report on Form 10-K with the...

22nd Century Granted FDA Guidance Meeting For X-22 Smoking Cessation Aid

22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is focused on reducing the harm caused by smoking, announced today that the Company has been granted a guidance meeting with the Center for Drug...